

1 **Antibiotic utilisation and the impact of antimicrobial resistance action plan on**  
2 **prescribing among older adults in New Zealand between 2005 and 2019**

3 **Authors**

4 Tichawona Chinzowu (MSc), Department of Life Sciences, University of Bath, United  
5 Kingdom

6 Te-yuan Chyou (PhD), Department of Biochemistry, University of Otago, Dunedin,  
7 New Zealand

8 Sandipan Roy (PhD), Department of Mathematical Sciences, University of Bath.

9 Hamish Jamieson (PhD), Associate Professor and Geriatrician, University of Otago  
10 Christchurch, Department of Medicine; Burwood Hospital, Christchurch, New  
11 Zealand

12 Prasad S Nishtala (PhD), Department of Life Sciences, University of Bath, United  
13 Kingdom

14 and

15 Centre for Therapeutic Innovation, University of Bath, United Kingdom

16

17 **Running title:** Antibiotic utilisation patterns

18

19 **Address correspondence to:**

20 Tichawona Chinzowu, Department of Pharmacy and Pharmacology, University of  
21 Bath, Bath

22 BA2 7AY, United Kingdom

23 Email: [tc888@bath.ac.uk](mailto:tc888@bath.ac.uk)

24

25 **Word count:** 3114 (excluding references)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26

27 **Abstract**

28

29 *Purpose:* The objectives of this study were to examine the overall utilisation of  
30 systematic antibiotics and the impact of the launch of the antimicrobial resistance  
31 action plan in older adults (65 years or more) living in New Zealand between 2005 and  
32 2019, using data from a national database (Pharmaceutical collections), stratified by  
33 antibiotic class, patient age, and sex.

34 *Methods:* Population-level systemic antibiotic dispensing data for older adults in New  
35 Zealand was analysed using repeated cross-sectional analysis between 01/01/2005  
36 and 31/12/2019. Data were extracted on the prescribed systemic antibiotics using a  
37 unique identifier for each case. Antibiotic utilisation was measured in DDD/TOPD  
38 values. In addition, an interrupted time series (ITS) analysis using the autoregressive  
39 integrated moving average (ARIMA) models was performed to determine the impact  
40 of the antimicrobial resistance action plan.

41 *Results:* Most of the antibiotic classes included in this study showed a significant  
42 overall decrease in utilisation ranging from 38.64% for sulphonamides to 80.64% for  
43 fluoroquinolones compared to 2005. Systemic antibiotic utilisation decreased by  
44 49.6% from the predicted usage between January 2018 and December 2019 following  
45 the launch of the antimicrobial resistance action plan. ARIMA model supported the  
46 reduction in utilisation with a step change of -0.2206 and slope change of -0.0029.

47 *Conclusions:* The ITS analysis has demonstrated that the intervention may have  
48 hugely impacted the antibiotic utilisation rate among older adults. Further studies are  
49 required to determine whether the reduced consumption rates of antibiotics are  
50 associated with reduced rates of antibiotic-associated adverse drug events such as  
51 acute kidney injury and haematological abnormalities.

52

53 **Keywords:** antimicrobial, consumption, prescribing, defined daily dose, elderly, time  
54 series, ARIMA model

55

## 56 **Introduction**

57

58 Inappropriate prescribing of antibiotics is an important driver of the rising global  
59 antibiotic resistance and a direct threat to the safety of patients due to the increased  
60 risk of adverse drug events such as acute kidney injury, haematologic, gastrointestinal,  
61 dermatologic and hepatobiliary abnormalities [1-3]. Outpatient and community  
62 utilisation of antibiotics is on the rise, with older adults (>65 years of age) receiving the  
63 highest prescribing rate compared to any other age group [4]. In the United States,  
64 older adults are one and half times more likely to receive antibiotics than younger  
65 adults in a year [5, 6]. In over 46% of visits involving non-bacterial respiratory tract  
66 infections, adults  $\geq 65$  receive unnecessary antibiotics, most of which are broad-  
67 spectrum agents [7, 8]. This increased rate of inappropriate prescribing raises  
68 concerns for older adults who are already at increased risk for serious adverse drug  
69 events due to age-related physiologic changes, comorbidities, and polypharmacy [9].  
70 Antibiotics, as a class, are the third commonest cause of adverse drug events among  
71 older adults. Nearly 15% of all emergency department visits for antibiotic-associated  
72 adverse drug events occur in older adults [10].

73 Specific antibiotic classes pose increased safety risks for older adults. For example,  
74 fluoroquinolones have been reported to put older adults at an elevated risk of serious  
75 adverse events, including tendon rupture, blood sugar disturbances, peripheral  
76 neuropathy, delirium and aortic dissection [11]. Macrolides, commonly prescribed to  
77 older adults, were associated with an elevated risk of cardiac arrhythmia and death,  
78 particularly in males [12]. Cotrimoxazole requires close monitoring in older adults due  
79 to the risk of pre-existing renal insufficiency necessitating dose adjustment [1].

80 There was a significant decrease in annual antibiotic usage between 2014 and 2018  
81 among most countries in the world Health Organisation (WHO) Europe region,  
82 including the United Kingdom, Germany, and Finland [13]. In their study, Andersson  
83 et al. [14] showed consistently higher antibiotic usage in Australia compared to  
84 Sweden. In New Zealand, systemic antibiotic consumption increased from 17.31 to  
85 25.79 DDD per 1000 per day between 2006 and 2014 [15]. In another New Zealand  
86 study, systemic antibiotics' consumption increased by 2% between 2010 and 2015  
87 among older adults [16].

88 For population-level health interventions, the interrupted time series (ITS) analysis is  
89 a valuable tool for evaluating their effectiveness, provided they were implemented at  
90 a well-defined time point [17]. Segmented regression is a commonly used approach  
91 for ITS analysis. However, it is not adequate in autocorrelation and seasonality [18].  
92 An alternative method, the ARIMA model, can accommodate both seasonality and  
93 autocorrelation [18].

94 Few studies describe the utilisation of systematic antibiotics at the population level,  
95 specifically among older adults in New Zealand, and how the utilisation rates respond  
96 to interventions primarily aimed at mitigating the development of antimicrobial  
97 resistance. Therefore, the objectives of this study were to examine the overall  
98 utilisation of systematic antibiotics and the impact of the launch of the antimicrobial  
99 resistance action plan in older adults (65 years or more) living in New Zealand between  
100 2005 and 2019, using data from a national database (Pharms), stratified by therapeutic  
101 class, age, and sex, based on the World Health Organisation Collaborating Centre for  
102 Drug Statistics Methodology (WHOC) Anatomical Therapeutic Chemical (ATC)  
103 classification.

104

## 105 **Methods**

106

### 107 *Study design*

108 Population-level systemic antibiotic dispensing data for older adults in New Zealand  
109 was analysed using repeated cross-sectional analysis between 1<sup>st</sup> January 2005 and  
110 31<sup>st</sup> December 2019. Data were extracted on the prescribed systemic antibiotics using  
111 a unique identifier for each case and analysed for utilisation in DDDs according to  
112 patients' antibiotic class, age, and sex. This study included dispensing claims data for  
113 all funded antibiotics by community pharmacies.

### 114 *Data source*

115 From 1st January 2005 to 31st December 2019, de-identified individual dispensing  
116 claims data for older adults (65 years and above) were extracted from the  
117 Pharmaceutical Collections [19, 20]. Pharmaceutical collections are the New Zealand  
118 Ministry of Health's national dispensing claims database which captures subsidised  
119 prescriptions dispensed by community pharmacies [21]. Antibiotics were categorised

120 using the ATC developed by WHOCC. The following antibiotic classes were included  
121 in this study: penicillins (J01C), macrolides (J01F), cephalosporins (J01D),  
122 tetracyclines (J01A), sulphonamides (J01E), fluoroquinolones (J01M),  
123 aminoglycosides (J01G), and ‘other antibiotics’ (J01X) [22]. In addition, metronidazole,  
124 nitrofurantoin, and vancomycin were classified as ‘Other antibiotics’ (J01X).

125

### 126 *Data analysis*

127 DDDs were computed for each antibiotic dispensed to an individual yearly and  
128 normalised by age group, antibiotic class, and sex at a population level. In this study,  
129 the DDD per 1000 older people per day (TOPD) measures the proportion of people  
130 being treated with a daily dose of antibiotic dispensed within a defined study area per  
131 1000 older people per day. Antibiotic utilisation by class, sex and age were also  
132 measured in DDD/TOPD values. The DDDs were computed for each antibiotic utilised  
133 by an individual yearly, per annual population size of New Zealand between 2005 and  
134 2019. The R statistical software (version 4.2.0) was used in all analyses [23].

### 135 *Interrupted time series analysis*

136 Using the R statistical software (version 4.2.0), we determined the effect of introducing  
137 the antimicrobial resistance action plan in January 2018 in New Zealand on antibiotic  
138 prescribing and utilisation rates among older adults. We performed ITS analysis using  
139 the ARIMA model [18] on monthly antibiotic utilisation rates to understand the effect  
140 of the implemented national antimicrobial resistance action plan [18]. Monthly  
141 DDD/TOPDs were computed above for the study period and population. The pre-  
142 intervention period was from January 2005 to December 2017, and the post-  
143 intervention period was from January 2018 to December 2019.

144 Firstly, the time series data was plotted to understand any patterns, including trends  
145 and seasonal variations. Then, the forecast R package [23] was used to determine  
146  $p/P$  and  $q/Q$  parameters. Next, stationarity was induced using the first-order difference  
147 where  $d = 1$  and  $D = 1$  for trend and seasonal differences, respectively. Next, we  
148 plotted the autocorrelation and partial autocorrelation functions (ACF/PACF) of  
149 stationarity data to view and confirm the ARIMA orders from the automated algorithms.  
150 Finally, the Ljung-Box test [18] was used to test whether residuals for the model were  
151 white noise or not.

152 Counterfactual values for the post-intervention period were determined and plotted  
153 together with observed values to visualise the impact of the intervention on the  
154 antimicrobial utilisation rate among older adults.

155

## 156 Results

157

### 158 Overall trend

159 Table 1 shows the percentage change in the utilisation of funded systemic antibiotics  
160 among older adults between 2005 and 2019 in New Zealand. Overall systemic  
161 antibiotic utilisation decreased by 56.28% between 2005 and 2019, averaging an  
162 annual decrease of 4.02% (Table 1). However, utilisation remained high from 2005 to  
163 2017, declining between 2018 and 2019 (Figure 1) following the implementation of the  
164 New Zealand Antimicrobial Resistance Action Plan [24].

165 **Table 1:** Utilization of antibacterial agents (in defined daily dose per 1000 older  
166 people per day [DDD/TOPD] values) between 2005 and 2019.

<i>Antibacterial class</i>	<i>Antibacterial name</i>	<i>Subsidized</i>	<i>WHO ATC classification</i>	<i>2005 DDD/TOPD</i>	<i>2019 DDD/TOPD</i>	<i>Change (%)</i>
Aminoglycosides	Gentamicin sulphate <sup>1</sup>	Partly	J01GB03	0.0023	0.0015	-31.9
	Tobramycin <sup>2</sup>	Partly	J01GB01	0.0038	0.0004	-88.8
<i>Subtotal</i>				<b>0.0059</b>	<b>0.0019</b>	<b>-68.0</b>
Cephalosporins	Cefuroxime axetil <sup>3</sup>	Partly	J01DC02	0.0092	0.0081	-12.0
	Cefaclor monohydrate	Yes	J01DC04	1.2259	0.7492	-38.9
	Ceftriaxone <sup>4</sup>	Partly	J01DD04	<0.0001	0.0010	5215.2
	Cefalexin	Yes	J01DB01	0.0863	0.6281	627.8
	Cefazolin	Yes	J01DB01	0.0031	0.0016	-50.0
<i>Subtotal</i>				<b>1.3249</b>	<b>1.3879</b>	<b>4.8</b>
Fluoroquinolones	Norfloxacin <sup>5</sup>	Partly	J01MA06	1.0518	0.0381	-96.4
	Ciprofloxacin	Yes	J01MA02	0.9586	0.3490	-63.6
<i>Subtotal</i>				<b>2.0104</b>	<b>0.3872</b>	<b>-80.7</b>
Macrolides	Azithromycin	Yes	J01FA10	0.0017	0.1147	6640.7
	Clindamycin	Yes	J01FF01	0.9075	0.7210	-20.6

	Roxithromycin	Yes	J01FA06	1.8771	0.6620	-64.7
	Clarithromycin <sup>6</sup>	Partly	J01FA09	0.0662	0.0119	-82.1
	Erythromycin ethyl succinate	Yes	J01FA01	1.8436	0.4295	-76.7
	Erythromycin stearate	Yes	J01FA01	0.1696	0.0131	-92.3
	Erythromycin (as lactobionate)	Yes	J01FA01	0.0001	<0.0001	-48.1
<b>Subtotal</b>				<b>4.8659</b>	<b>1.952243</b>	<b>-59.9</b>
<b>Other antibiotics</b>	Metronidazole	Yes	J01XD01	0.9267	0.3647	-60.7
	Nitrofurantoin	Yes	J01XE01	1.2779	1.0226	-20.0
	Vancomycin <sup>7</sup>	Partly	J01XA01	0.0029	0.0033	<b>13.8</b>
<b>Subtotal</b>				<b>2.2075</b>	<b>1.3906</b>	<b>-37.0</b>
<b>Penicillins</b>	Amoxicillin-clavulanic acid	Yes	J01CR02	4.9023	1.0866	-77.8
	Amoxicillin	Yes	J01CA04	2.5529	1.2829	-49.8
	Benzathine benzylpenicillin	Yes	J01CE08	0.1901	0.0071	-96.3
	Dicloxacillin	No	J01CF01	0.0656	0	NA
	Penicillin G	Yes	J01CE09	0.0017	0.0001	-91.2
	Penicillin V	Yes	J01CE02	0.2428	0.0955	-60.7
	Flucloxacillin	Yes	J01CF05	2.0635	1.3127	-36.4
<b>Subtotal</b>				<b>10.0188</b>	<b>3.7848</b>	<b>-62.2</b>
<b>Sulphonamides</b>	Co-trimoxazole	Yes	J01EE01	0.7813	0.4340	-44.5
	Trimethoprim	Yes	J01EA01	1.7506	1.1192	-36.1
<b>Subtotal</b>				<b>2.5319</b>	<b>1.5533</b>	<b>-38.7</b>
<b>Tetracyclines</b>	Doxycycline	Yes	J01AA02	5.6786	2.0642	-63.7
<b>Subtotal</b>				<b>5.6786</b>	<b>2.0642</b>	<b>-63.7</b>
<b>Total (all antibacterial agents)</b>				<b>28.6440</b>	<b>12.5221</b>	<b>-56.3</b>

167 Notes:

- 168 1. Gentamicin sulphate subsidised only if prescribed for a dialysis or cystic fibrosis
- 169 patient or complicated urinary tract infection and the prescription is endorsed
- 170 accordingly.
- 171 2. Tobramycin subsidised only if prescribed for dialysis or cystic fibrosis patient and the
- 172 prescription is endorsed accordingly.
- 173 3. Cefuroxime axetil subsidised only if prescribed for prophylaxis of endocarditis and
- 174 the prescription is endorsed accordingly.

- 175 4. Ceftriaxone subsidised only if prescribed for a dialysis or cystic fibrosis patient, or  
176 the treatment of gonorrhoea, or the treatment of pelvic inflammatory disease, or the  
177 treatment of suspected meningococcal disease, and the prescription or PSO is endorsed  
178 accordingly
- 179 5. Norfloxacin subsidised only if prescribed for a patient with an uncomplicated  
180 urinary tract infection that is unresponsive to a first line agent or with proven resistance  
181 to first line agents and the prescription is endorsed accordingly.
- 182 6. Clarithromycin subsidized for Helicobacter pylori infections only.
- 183 7. Vancomycin subsidized only if prescribed for a dialysis or cystic fibrosis patient or for  
184 prophylaxis of endocarditis or for treatment of Clostridium difficile following  
185 metronidazole failure and the prescription is endorsed accordingly.

186

187 **Source for notes 1-7:** PHARMAC, Online Pharmaceutical Schedule. Available at:

188 <https://schedule.pharmac.govt.nz/ScheduleOnline.php>. Accessed on 03/06/2022.

189

190 Most antibiotic classes included in this study showed a significant decrease in  
191 utilisation ranging from 38.64% for sulphonamides to 80.64% for fluoroquinolones.  
192 However, cephalosporins showed a 4.76% increase in usage during the study period,  
193 and this was largely attributed to the increased utilisation of cephalexin and  
194 ceftriaxone. Although macrolide utilisation decreased significantly, the utilisation of  
195 azithromycin increased by just over 66 times that of 2005 by the end of 2019.  
196 Vancomycin only showed an overall increase of 13.8% in utilisation during the study  
197 period. In 2019, the top four single most utilised antibiotics were doxycycline  
198 (DDD/TOPD = 2.06), flucloxacillin (DDD/TOPD = 1.31), amoxicillin (DDD/TOPD =  
199 1.28), and trimethoprim (DDD/TOPD = 1.12) (Table 1).

#### 200 *Utilisation by antibiotic classes*

201 Except for aminoglycosides and fluoroquinolones, all included antibiotic classes  
202 showed a steady increase in utilisation until 2016 (Figure 1), followed by a sharp  
203 decline. Fluoroquinolone utilisation started declining in 2012, while aminoglycoside  
204 utilisation remained very low. The most utilised antibiotic classes were penicillins  
205 (DDD/TOPD = 3.78), tetracyclines (DDD/TOPD = 2.06), and macrolides (DDD/TOPD  
206 = 1.95) (Table 1). The biggest reduction in utilisation between 2005 and 2019 was on  
207 fluoroquinolones, which dropped by 80.7% (Table 1).



208 *Utilisation by antibiotic class and age*

209 The total systemic antibiotic consumption increased with age but remained relatively  
210 steady from 2005 to 2017 (Figure 2). Penicillins were the most utilised antibiotics  
211 across all age groups. In addition, the DDD/TOPD for all classes, except  
212 aminoglycosides, increased with age.

213 *Utilisation by antibiotic class, age, and sex*

214 The rate of antibiotic consumption was constant in both males and females for all  
215 antibiotic classes (except fluoroquinolones) and age groups, except for the 95 years  
216 old and above males, whose consumption rate has been steadily increasing in all  
217 antibiotic classes (Figure 3). Between 65 and 79 years of age, antibiotic utilisation was  
218 similar for both sexes. Females had higher utilisation than males from age 80 to 94  
219 years. Among those 95 years and above, males had greater utilisation than females.  
220 Fluoroquinolone utilisation has been decreasing in all age groups for both males and  
221 females as early as 2012, except among the 95 years and above males, where the  
222 decrease in consumption started in about 2015.

223 *Interrupted time series analysis*

224 The observed data showed a slight upward trend and possible seasonality on analysis  
225 (Supporting file, Figures S1, S2 and S3). Before the intervention, the visible trend and  
226 seasonality determined stationarity by first difference ( $d = 1$ ) and seasonal difference  
227 ( $D = 1$ ). According to the undifferenced and differenced ACF/PACF plots obtained, the  
228 former showed autocorrelation at lag 12 (Supporting file, figure S4 and S5). After  
229 running the automated algorithm in R, the best model selected was  $(3,1,0) (0,1,1) [12]$ .  
230 Thus, autocorrelation order ( $p$ ) was 3, the moving average order ( $q$ ) was 0, the  
231 autocorrelation order for the seasonal part ( $P$ ) was 0, and the moving average order  
232 for the seasonal part ( $Q$ ) was 1. The  $p$ -value for the Ljung-Box test for white noise was  
233 0.51 at 36 lags (Supporting file, figure S6); therefore, the chosen model had a good fit.  
234 Figure 4 is the final ARIMA model showing predicted values in the absence of an  
235 antimicrobial resistance action plan (counterfactual) compared to observed values.  
236 The estimated step change was minus 0.2206 (95% CI: -0.4619 – 0.0207) and the  
237 estimated change in slope was -0.0029 (95% CI: -0.0097 – 0.0039).

238

## 239 **Discussion**

240

### 241 *Overall trend*

242 This study found that the overall utilisation of subsidised systemic antibiotics among  
243 older people in New Zealand dropped by 49.6% of the predicted utilisation rate for  
244 2018/2019 following the implementation of the antimicrobial resistance action plan  
245 [24]. In a previous study, systemic antibiotic utilisation was reported to have increased  
246 49% between 2006 and 2014 in New Zealand [15]. This increase is also reflected in  
247 this study, where utilisation of most antibiotic classes steadily increased until 2015  
248 (Figure 1 and table 2). However, this was followed by a sharp decrease to more than  
249 56% below the 2005 utilisation rate between 2018 and 2019.

250 We concluded that implementing the antimicrobial resistance action plan contributed  
251 significantly, but not exclusively, to the significant drop in total antibiotic utilisation rates  
252 in New Zealand in 2018 and 2019. In 2015, Thomas [25] called for immediate action  
253 to reduce antimicrobial prescribing in New Zealand, particularly in the community  
254 where most infections were self-limiting. His recommendations included not  
255 prescribing antibiotics where the infection was likely viral, not prescribing antibiotics  
256 for sore throat in all over eighteen (except for Māori and non-Pacific ethnicities),  
257 substituting amoxicillin-clavulanic acid with penicillin for *Streptococcus pyogenes* skin  
258 infections, and no fluoroquinolones for urinary tract infections. These  
259 recommendations were supported by the Antibiotic Consumption in New Zealand,  
260 2006 – 2014 surveillance report [26]. Significant reduction in amoxicillin and  
261 amoxicillin-clavulanic acid utilisation rates would greatly impact total antibiotic  
262 utilisation since these two antibiotics contributed more than 42% of the total antibiotic  
263 utilisation rates for the period 2006 - 2014 [26]. The utilisation of these penicillins, and  
264 to a lesser extent macrolides and tetracyclines, followed a seasonal pattern with peaks  
265 during the winter months (June to August) and troughs during the summer months  
266 (December to February) in New Zealand [26]. The highest use of penicillins was  
267 reported among older adults of the Pacific Peoples, European (and other), Middle  
268 Eastern, Latin American, and African (MELAA) ethnicities. The utilisation of amoxicillin  
269 and amoxicillin-clavulanic acid doubled between 2006 and 2014, possibly overusing  
270 due to overlapping clinical features of indicated conditions with viral infections [26].

271 The antimicrobial resistance action plan was developed through a collaboration of  
272 various human, animal and agricultural stakeholders to respond to the ever-rising  
273 global challenge of antimicrobial resistance [24]. The implementation would be spread  
274 over five years from 2017, with the first year mainly for fact-finding, training, and  
275 resource mobilisation before rolling out the activities from year two onwards. One of  
276 the main objectives focussed on the optimisation of the use of antimicrobial medicines,  
277 whereby in 2017, the focus was on investigating inequalities in antimicrobial  
278 prescribing in community hospital settings and, from 2018, rolling out the appropriate  
279 activities to reduce antimicrobial consumption while promoting appropriate prescribing  
280 began [24]. In our study, we, therefore, considered January 2018 as the date of starting  
281 the measures recommended to reduce antimicrobial utilisation in New Zealand.

282 The ITS analysis, as shown in figure 4, has demonstrated that this intervention  
283 significantly impacted the antibiotic utilisation rate among older adults. The huge drop  
284 in total antibiotic utilisation rate was probably due to a huge drop in prescribing  
285 amoxicillin or amoxicillin-clavulanic acid following the implementation of the action  
286 plan. The Best Practice Advocacy Centre for New Zealand (BPACNZ) supported this  
287 and noted a sustained decrease in dispensed oral antibiotic prescriptions per 1000  
288 registered patients [27]. In 2018 and 2019, there was an average of 3% to 5% annual  
289 drop in dispensed antibiotic prescriptions, according to the BPACNZ [27]. This  
290 decrease was attributed to New Zealand's improved antimicrobial stewardship. Our  
291 findings were further supported by Thomas et al.[28], who concluded that there was  
292 an overall decrease in dispensing of antibiotics among adults 60 years or above in  
293 New Zealand between 2015 and 2018. In their study, Thomas et al.[28] found that  
294 community antibiotic dispensing, measured as defined daily doses per 1,000  
295 inhabitants per day, decreased by 4.6% per year during 2015-2018, with large  
296 reductions in dispensing of amoxicillin-clavulanate [28].

297 In a recent study, overall antibiotic utilisation was consistently higher in Australia  
298 compared to Sweden between 2006 and 2018 [14]. In Australia, the overall utilisation  
299 was steady, ranging from 21.8 DDD/TOPD in 2006 to 22.2 DDD/TOPD in 2018,  
300 whereas Sweden experienced a 26.2% decrease in utilisation between 2006 and  
301 2018. Compared to Australia and Sweden, our results showed that New Zealand's  
302 drop in overall antibiotic utilisation was the fastest, which could have been

303 necessitated by the government's strong response to the increasing global challenge  
304 of antimicrobial resistance in 2016 [29].

305 The top four most utilised antibiotic agents in 2019 were doxycycline, flucloxacillin,  
306 amoxicillin, and trimethoprim (Table 1). This finding agrees with previous studies  
307 where doxycycline and amoxicillin consistently appeared on the top list of heavily  
308 consumed single antibiotics [14, 15]. However, in a separate US study, the top four  
309 most used antibiotics among older adults (65 years or more) were azithromycin,  
310 ciprofloxacin, amoxicillin, and cefalexin [30]. The differences in the usage of individual  
311 antibiotics are possibly due to different local and national antibiotic stewardship  
312 policies, treatment guidelines, subsidy arrangements, and non-adherence. [13, 31,  
313 32].

#### 314 *Utilisation by antibiotic class*

315 This study showed that in 2019 the most utilised antibiotic classes were penicillins,  
316 tetracyclines, and macrolides (Table 1). Previous studies have also found penicillins,  
317 extended-spectrum penicillins and beta-lactamase sensitive penicillins as the most  
318 heavily consumed antibiotic classes in New Zealand, Australia, and Sweden,  
319 respectively [14, 15]. This general agreement in utilisation trends, by class, of systemic  
320 antibiotics may indicate an internationally improved antibiotic stewardship.

#### 321 *Utilisation by age group and sex*

322 In this study, antibiotic utilisation rates generally varied with age and sex, increasing  
323 in the older age group (Figure 2). Williamson et al. [15] also found that antibiotic  
324 utilisation rates increased with age among the New Zealand population and were  
325 significantly and consistently higher in females than males between 2006 and 2014.  
326 Our study showed that antibiotic utilisation was similar for males and females between  
327 65 and 79 years. However, females had a higher antibiotic utilisation rate than males  
328 between the ages of 80 and 94, and men of 95 years and above had a higher utilisation  
329 rate than women (Figure 3). Marquez et al.'s study support this finding that after age  
330 65, men have higher innate and pro-inflammatory activity and lower adaptive activity  
331 than women [33].

#### 332 **Limitations**

333 One of the major limitations of dispensing data is the lack of information on antibiotics'  
334 indications and appropriateness. Therefore, adherence to antimicrobial therapy by the  
335 patients is not captured and accounted for when using such datasets. We used data  
336 for dispensing claims for funded antibiotics made by community pharmacies only, thus  
337 possibly missing data on unfunded antibiotics prescribed to the study population  
338 during the study period. Additionally, the Pharmaceutical Collections database does  
339 not include information about medicines dispensed in hospitals [34], so antibiotic  
340 exposure may have been underestimated if older adults received the drugs during  
341 hospitalisation. Our post-intervention observation period was relatively short (from  
342 January 2018 to December 2019) and therefore might not reflect the true impact of the  
343 intervention. Other factors besides the antimicrobial action plan may have played a  
344 significant role in the huge drop in antibiotic utilisation rates between 2018 and 2019.  
345 For example, there was already an annual 4.6% drop in antibiotic utilisation rate three  
346 years before the launch of the antimicrobial intervention plan [28].

### 347 **Strengths**

348 The reimbursement system in New Zealand captures greater than 95% of the  
349 prescription coverage of older adults' census population, strengthening our study  
350 findings' validity. This study also acts as a proxy measure of adherence to national  
351 antibiotic prescribing policies and stewardship guidelines among older adults in New  
352 Zealand. In addition, the validity of our findings was strengthened by using the ARIMA  
353 models to perform the interrupted time series analysis to investigate the impact of the  
354 antimicrobial resistance action plan on antibiotic utilisation. Previous studies have  
355 demonstrated the utility and reliability of ARIMA models for evaluating population-level  
356 health interventions [18].

### 357 **Conclusion**

358

359 This study provides valuable information on the consumption of systemic antibiotics  
360 among the 65 years or above sub-population of New Zealand. It has also shown the  
361 effectiveness of the antimicrobial resistance action plan introduced by the government  
362 of New Zealand to mitigate antibiotic resistance by reducing inappropriate  
363 antimicrobial utilisation. The ITS analysis has demonstrated that this intervention  
364 hugely impacted the antibiotic utilisation rate among older adults. As a result, there  
365 was a significant reduction in the overall utilisation of systematic antibiotics between

366 2005 and 2019 among older adults in New Zealand. However, there were some age  
367 and sex differences in the consumption rates of antibiotics among the studied  
368 population. Further studies are required to determine whether the reduced  
369 consumption rates of antibiotics are associated with reduced rates of antibiotic-  
370 associated adverse drug events such as acute kidney injury and haematological  
371 abnormalities.

372

373 **Ethics statement:** The Departmental Research and Ethics Officer at the University  
374 of Bath assessed the ethical implications of research activity (EIRA) and approved  
375 this study on behalf of the University of Bath's Research, Integrity, and Ethics  
376 committee. Approval number EIRA 1-4048.

### 377 **Acknowledgement**

378

379 The authors thank the Analytical Services, Ministry of Health of New Zealand, for  
380 supplying the data extracted from the Pharms database.

381

### 382 **Author contributions**

383 TC (Bath) serves as the first author of the manuscript. He led all the stages of the development  
384 of this manuscript while PN supervised. TC (Otago), TC (Bath), and PN contributed to  
385 statistical analysis, interpretation of results, and manuscript revision. SR and HJ also  
386 contributed to interpreting the results and manuscript revision. All authors approved the final  
387 manuscript.

388

389 **Conflict of interest:** The authors have no conflicts of interest to declare

390

391 **Funding:** No funding was received

392

393 **Data availability:** The data is owned by the Analytical Services, Ministry of Health,  
394 New Zealand, so supporting data is not available



## 396 **References**

397


- 398 1. Pulia MS, Keller SC, Crnich CJ, Jump RLP, Yoshikawa TT. Antibiotic  
399 Stewardship for Older Adults in Ambulatory Care Settings: Addressing an Unmet  
400 Challenge. *J Am Geriatr Soc.* 2020;68(2):244-9.
- 401 2. Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of Adverse  
402 Events With Antibiotic Use in Hospitalized Patients. *JAMA Intern Med.*  
403 2017;177(9):1308-15.
- 404 3. Hagiya H, Kokado R, Ueda A, Okuno H, Morii D, Hamaguchi S, et al.  
405 Association of Adverse Drug Events with Broad-spectrum Antibiotic Use in  
406 Hospitalized Patients: A Single-center Study. *Intern Med.* 2019;58(18):2621-5.
- 407 4. King LM, Bartoces M, Fleming-Dutra KE, Roberts RM, Hicks LA. Changes in  
408 US Outpatient Antibiotic Prescriptions From 2011-2016. *Clin Infect Dis.*  
409 2020;70(3):370-7.
- 410 5. Kabbani S, Palms D, Bartoces M, Stone N, Hicks LA. Outpatient Antibiotic  
411 Prescribing for Older Adults in the United States: 2011 to 2014. *J Am Geriatr Soc.*  
412 2018;66(10):1998-2002.
- 413 6. Fleming-Dutra KE, Hersh AL, Shapiro DJ, Bartoces M, Enns EA, File TM, Jr.,  
414 et al. Prevalence of Inappropriate Antibiotic Prescriptions Among US Ambulatory  
415 Care Visits, 2010-2011. *Jama.* 2016;315(17):1864-73.
- 416 7. Silverman M, Povitz M, Sontrop JM, Li L, Richard L, Cejic S, et al. Antibiotic  
417 Prescribing for Nonbacterial Acute Upper Respiratory Infections in Elderly Persons.  
418 *Ann Intern Med.* 2017;166(11):765-74.
- 419 8. Schmidt ML, Spencer MD, Davidson LE. Patient, Provider, and Practice  
420 Characteristics Associated with Inappropriate Antimicrobial Prescribing in  
421 Ambulatory Practices. *Infect Control Hosp Epidemiol.* 2018;39(3):307-15.
- 422 9. Tanner LA, Baum C. Spontaneous adverse reaction reporting in the elderly.  
423 *Lancet.* 1988;2(8610):580.
- 424 10. Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits  
425 for antibiotic-associated adverse events. *Clin Infect Dis.* 2008;47(6):735-43.
- 426 11. Sakoulas G. Adverse effects of fluoroquinolones: where do we stand now.  
427 *NEJM Journal Watch.* 2019;13.




- 428 12. Rao GA, Mann JR, Shoaibi A, Bennett CL, Nahhas G, Sutton SS, et al.  
429 Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and  
430 death. *Ann Fam Med*. 2014;12(2):121-7.
- 431 13. Robertson J, Vlahović-Palčevski V, Iwamoto K, Högberg LD, Godman B,  
432 Monnet DL, et al. Variations in the Consumption of Antimicrobial Medicines in the  
433 European Region, 2014-2018: Findings and Implications from ESAC-Net and WHO  
434 Europe. *Front Pharmacol*. 2021;12:639207.
- 435 14. Andersson K, van Driel M, Hedin K, Hollingworth S, Merlo G. Antibiotic use in  
436 Australian and Swedish primary care: a cross-country comparison. *Scand J Prim  
437 Health Care*. 2022:1-9.
- 438 15. Williamson DA, Roos R, Verrall A, Smith A, Thomas MG. Trends,  
439 demographics and disparities in outpatient antibiotic consumption in New Zealand: a  
440 national study. *J Antimicrob Chemother*. 2016;71(12):3593-8.
- 441 16. Tomlin AM, Woods DJ, Reid JJ, Tilyard MW. Trends in prescription medicine  
442 use by older people in New Zealand 2010- 2015: a national population-based study.  
443 *N Z Med J*. 2020;133(1513):61-72.
- 444 17. Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for  
445 the evaluation of public health interventions: a tutorial. *Int J Epidemiol*.  
446 2017;46(1):348-55.
- 447 18. Schaffer AL, Dobbins TA, Pearson SA. Interrupted time series analysis using  
448 autoregressive integrated moving average (ARIMA) models: a guide for evaluating  
449 large-scale health interventions. *BMC Med Res Methodol*. 2021;21(1):58.
- 450 19. Ministry of Health. Pharmaceutical collection. Publicly funded pharmaceutical  
451 dispensings between 1 January 2005 and 31 December 2016. . 2017.
- 452 20. collection. MoHP. Publicly funded pharmaceutical dispensings between 1 July  
453 2012 and 31 December 2019 for a selected cohort. 2020.
- 454 21. Narayan SW, Hilmer SN, Horsburgh S, Nishtala PS. Anticholinergic  
455 component of the Drug Burden Index and the Anticholinergic Drug Scale as  
456 measures of anticholinergic exposure in older people in New Zealand: a population-  
457 level study. *Drugs Aging*. 2013;30(11):927-34.
- 458 22. Who Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index  
459 2022 [cited 2022 31/05/2022]. Available from:  
460 [https://www.whocc.no/atc\\_ddd\\_index/](https://www.whocc.no/atc_ddd_index/).

- 461 23. R Core Team. R: A language and environment for statistical computing.: R  
462 Foundation for Statistical Computing, Vienna, Austria.; 2022 [updated April 2022;  
463 cited 2022 05/05/2022]. R-4.2.0:[Available from: <https://www.R-project.org/>.  
464 24. Ministry of Health and Ministry for Primary Industries. New Zealand  
465 Antimicrobial Resistance Action Plan. In: Industries. MoHaMfP, editor. Wellington:  
466 Ministry of Health; 2017.  
467 25. Thomas M. Upfront: Time to reduce antibiotic prescribing – NOW. Best  
468 Practice Journal New Zealand. 2015(68).  
469 26. Williamson DA, Roos, R.F., Verrall, A. Antibiotic Consumption in New  
470 Zealand, 2006-2014. In: Zealand. TloESaRLPN, editor. Porirua2016.  
471 27. Best Practice Advocacy Centre New Zealand. National Report: Overview of  
472 national dispensing during 2020 2021 [cited 2022 21/10/2022]. Available from:  
473 <https://bpac.org.nz/report/2020/national-dispensing.aspx#dispensing>.  
474 28. Thomas M, Tomlin A, Duffy E, Tilyard M. Reduced community antibiotic  
475 dispensing in New Zealand during 2015-2018: marked variation in relation to primary  
476 health organisation. N Z Med J. 2020;133(1518):33-42.  
477 29. Ministry of Health and Ministry for Primary Industries. Antimicrobial  
478 Resistance: New Zealand's current situation and identified areas for action. In:  
479 Industries MoHaMfP, editor. Wellington: Ministry of Health; 2017.  
480 30. Olesen SW, Barnett ML, MacFadden DR, Lipsitch M, Grad YH. Trends in  
481 outpatient antibiotic use and prescribing practice among US older adults, 2011-15:  
482 observational study. Bmj. 2018;362:k3155.  
483 31. Auta A, Hadi MA, Oga E, Adewuyi EO, Abdu-Aguye SN, Adeloye D, et al.  
484 Global access to antibiotics without prescription in community pharmacies: A  
485 systematic review and meta-analysis. J Infect. 2019;78(1):8-18.  
486 32. Browne AJ, Chipeta MG, Haines-Woodhouse G, Kumaran EPA, Hamadani  
487 BHK, Zaraa S, et al. Global antibiotic consumption and usage in humans, 2000-18: a  
488 spatial modelling study. Lancet Planet Health. 2021;5(12):e893-e904.  
489 33. Márquez EJ, Chung CH, Marches R, Rossi RJ, Nehar-Belaid D, Eroglu A, et  
490 al. Sexual-dimorphism in human immune system aging. Nat Commun.  
491 2020;11(1):751.  
492 34. Donald S, Sharples K, Barson D, Horsburgh S, Parkin L. Patterns of  
493 prescription medicine dispensing before and during pregnancy in New Zealand,  
494 2005-2015. PLoS One. 2020;15(6):e0234153.






**Figure 1:** Systemic antibacterial utilisation by antibiotic class, expressed as defined daily doses per thousand older people per day (DDD/TOPD), from 2005 to 2019 for older adults (65 years or more) in New Zealand.



**Figure 2:** Systemic antibacterial class consumption by age group, expressed as defined daily doses per thousand older people per day (DDD/TOPD), from 2005 to 2019 for older adults (65 years or more) in New Zealand




1

2 **Figure 3:** Systemic antibacterial class consumption by age group and sex, expressed as defined daily doses per thousand older  
 3 people per day (DDD/TPD), from 2005 to 2019 for older adults (65 years or more) in New Zealand.



## Interrupted time series analysis: Final ARIMA model



**Figure 4:** Final ARIMA model showing predicted values in the absence of antimicrobial resistance action plan (counterfactual) compared to observed values.

Step = -0.2206 (95% CI: -0.4619 – 0.0207).

Ramp = -0.0029 (95% CI: -0.0097 – 0.0039)

Key:

Counterfactual = Red. Observed values = Blue. Intervention date = Grey dotted vertical